Technology
Health
Biotechnology

Syros

$7.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.26%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Syros and other stocks, options, ETFs, and crypto commission-free!

About SYRS

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Read More The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Employees
76
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
256.29M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
161.39K
High Today
$7.66
Low Today
$7.14
Open Price
$7.58
Volume
95.36K
52 Week High
$13.16
52 Week Low
$5.17

Collections

Technology
Health
Biotechnology
Cancer Prevention
2016 IPO
US
North America
Female CEOs

SYRS Earnings

-$0.58
-$0.52
-$0.45
-$0.39
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.